Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...949596979899100101102103104...10651066»
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Transient Mild Photothermia Improves Therapeutic Performance of Oral Nanomedicines with Enhanced Accumulation in The Colitis Mucosa. (Pubmed Central) -  Dec 12, 2023   
    Upon oral administration of hydrogel-encapsulating P127-AuS@CURs plus intestinal intra-lumen TMP, their therapeutic effects against acute and chronic UC are demonstrated to be superior to those of a widely used clinical drug, dexamethasone...The treatment of P127-AuS@CURs (+ TMP) elevated the proportions of beneficial bacteria (e.g., Lactobacillus and Lachnospiraceae), whose metabolites could also mitigate colitis symptoms by regulating genes associated with anti-oxidation, anti-inflammation, and wound healing. Overall, the intestinal intra-lumen TMP offers a promising approach to enhance the therapeutic outcomes of noninvasive medicines against UC.
  • ||||||||||  Carvykti (ciltacabtagene autoleucel) / J&J
    Cost per Responder Analysis of Patients with Lenalidomide-Refractory Multiple Myeloma Who Received Cilta-Cel from the Cartitude-4 Trial () -  Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_1231;    
    P3
    In the phase 3 trial CARTITUDE-4 (NCT04181827), cilta-cel demonstrated improved efficacy vs standard of care (SOC; daratumumab plus pomalidomide and dexamethasone [DPd] or pomalidomide plus bortezomib and dexamethasone [PVd]) with an overall response rate (ORR) of 84.6% vs 67.3% and ?complete response (CR) of 73.1% vs 21.8%. CPR analysis of CARTITUDE-4 data estimated that cost per complete responder and cost per month in PFS for cilta-cel were remarkably lower than DPd or PVd primarily driven by treatment acquisition and subsequent treatment costs demonstrating the substantial clinical and economic benefit cilta-cel offers for pts with RRMM.
  • ||||||||||  Carvykti (ciltacabtagene autoleucel) / J&J
    Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma and 1 () -  Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_1226;    
    P3
    Introduction: CARTITUDE-4 (NCT04181827) is a phase 3 trial comparing ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen chimeric antigen receptor-T cell (CAR-T) therapy, with standard of care (SOC; pomalidomide, bortezomib, and dexamethasone [PVd] or daratumumab, pomalidomide, and dexamethasone [DPd]) in patients (pts) with lenalidomide (len)-refractory multiple myeloma (MM). Similar to data from CARTITUDE-2 cohort A, the CARTITUDE-4 as-treated set analysis supports the potential of cilta-cel for prolonged disease control, benefiting pts with MM as early as after first relapse.
  • ||||||||||  Breyanzi (lisocabtagene maraleucel) / BMS, Kineret (anakinra) / SOBI, Yescarta (axicabtagene ciloleucel) / Gilead
    Use of Intrathecal Chemotherapy for Corticosteroid-Refractory Icans in B-Cell Lymphoma Patients Treated with CART () -  Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_1199;    
    After IT, the median cumulative dose of dexamethasone was 351 mg (140-1182), and 6 (67%) received anakinra...Conclusion. IT chemotherapy can represent an effective treatment strategy for corticosteroid-refractory ICANS; larger prospective studies are needed to optimize its schedule and to identify biomarkers of response and resistance.
  • ||||||||||  cyclophosphamide / Generic mfg.
    Budesonide Use for Grade 2 Gastrointestinal Graft-Versus-Host Disease after Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis () -  Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_1031;    
    The introduction of post-transplant cyclophosphamide (PTCy) has allowed the ability to reduce immunological complications and increase the pool of suitable donors, increasing access to many HLA-disparate patients in the HLA mismatched setting with acceptable graft-versus-host disease (GVHD) rates, and even challenged the conventional use of calcineurin and methotrexate based GVHD prophylaxis strategies in the HLA-identical donor setting for HCT. In patients who underwent HCT with PTCy based GVHD prophylaxis with isolated grade 2 GI GVHD budesonide monotherapy resulted in good responses without the addition of systemic therapy, sparing the majority of patients toxicities associated with systemic treatment.
  • ||||||||||  Jakafi (ruxolitinib) / Novartis, Incyte
    An in Vitro Patient-Derived Model of Bronchiolitis Obliterans Syndrome Yields New Insight into Steroid Sensitivity and Resistance () -  Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_1005;    
    HSD11B2 metabolizes steroids such as prednisolone and renders them inactive, suggesting possible benefit from use of dexamethasone, which the gene does not inactivate, or targeted HSD11B2 inhibitors (Sai et al, 2011)...GADD45G (55-fold increase, padj=0.01) functions as a negative regulator of the Jak-Stat3 pathway and may modify response to ruxolitinib...Conclusions Our novel patient specific model of BOS has identified important pathways and therapeutic targets in BOS. The model will be used to further test clinical therapeutic applications.
  • ||||||||||  Tecvayli (teclistamab) / Genmab, J&J
    Outpatient Management of CAR-T and Teclistamab for Patients with Lymphoma and Multiple Myeloma () -  Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_954;    
    Our data showed that additional advances in outpatient practice, including initial outpatient management of CRS and home visits are feasible, safe and reduce hospital resource utilization. Updated data on additional patients and new BsAb in practice will be presented.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Actemra IV (tocilizumab) / Roche, JW Pharma, Kineret (anakinra) / SOBI
    Incidence and Outcomes of Cytomegalovirus Reactivation after Chimeric Antigen Receptor T Cell Therapy () -  Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_946;    
    CMV reactivation is a common complication of CAR T cell therapy in CMV seropositive individuals. Although confirmatory studies are needed, our data shows that immunosuppression, in particular steroids, for management of CAR T cell toxicities is a major risk factor for CMV reactivation, and close monitoring might be indicated in this setting.
  • ||||||||||  cyclophosphamide / Generic mfg.
    Journal:  Favorable evolution of severe paraquat poisoning. Treatment with gastric lavage, activated charcoal, cyclophosphamide (Pubmed Central) -  Dec 11, 2023   
    These observations raise three questions in the treatment of paraquat intoxication: the effectiveness of HD, the interest of its association with the above therapies in the prevention of pulmonary fibrosis, and the need for infectious prevention and thromboembolism. Furthermore, the absence of a paraquatemia assay cannot constitute a limitation for management, and hemoperfusion on an inaccessible charcoal column can be replaced by an HD usually available.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Glucocorticoids modulate neural activity via a rapid non-genomic effect on Kv2.2 channels in the central nervous system. (Pubmed Central) -  Dec 11, 2023   
    Bovine serum albumin-conjugated dexamethasone, a membrane-impermeable agonist of the glucocorticoid receptor, could mimic the effect of cortisol on Kv2.2 channels...In conclusion, glucocorticoids can rapidly activate Kv2.2 channels through membrane-associated glucocorticoid receptors via the ERK1/2 signaling pathway, suppress presynaptic action potential firing, and inhibit synaptic transmission and plasticity. This may be a universal mechanism of the glucocorticoid-induced non-genomic effects in the central nervous system.
  • ||||||||||  hydrocortisone / Generic mfg.
    Journal, HEOR:  Health-Related Quality of Life in Patients with Primary Adrenal Insufficiency. (Pubmed Central) -  Dec 9, 2023   
    AddiQoL scores correlated negatively with the age of diagnosis (p = 0.015). (4) Female sex, higher gonadotropins level, and older age at diagnosis were associated with impaired HRQoL in the studied group of patients with PAI.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: Results of a large survey and clinical guidance recommendations from the IFM group. (Pubmed Central) -  Dec 9, 2023   
    Venous thromboembolism (VTE) remains a critical issue in the management of patients with multiple myeloma (MM), particularly when immunomodulatory drugs (IMiDs) combined with dexamethasone therapy are being prescribed as first-line and relapse therapy...However, in order to implement a personalized continuous improvement strategy, clinicians must to be organized to collect all the data regarding this management. In other situations, thromboprophylaxis should be evaluated by using risk models and after careful evaluation of the risk/benefit ratio.
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
    Beyond Paclitaxel: A Review of Non-Paclitaxel-Based Antiproliferative Therapies for Peripheral Arterial Disease Management () -  Dec 9, 2023 - Abstract #SIR2024SIR_1259;    
    Exploration of safety and efficacy of other drug agents, including biolimus A9, novolimus, tacrolimus, pimecrolimus, dexamethasone, and curcumin, for potential use in arterial revascularization and their applicability in PAD. Conclusion and/or Teaching Points: Discussing evidence-based outcomes regarding the safety, efficacy, and applicability of alternative agents.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  E47 as a novel glucocorticoid-dependent gene mediating lipid metabolism in patients with endogenous glucocorticoid excess. (Pubmed Central) -  Dec 8, 2023   
    Control subjects underwent ACTH stimulation tests and dexamethasone suppression tests to analyze short-term regulation of E47...E47 gene expression showed a positive correlation with total serum cholesterol (p = 0.0036), low-density lipoprotein cholesterol (p = 0.0157), and waist-arm ratio (p = 0.0138) in patients with CS in remission. E47 is a GC-dependent gene that is upregulated in GC excess potentially aiming at reducing metabolic glucocorticoid side effects such as
  • ||||||||||  hydrocortisone / Generic mfg.
    Journal:  Major immunophenotypic abnormalities in patients with primary adrenal insufficiency of different etiology. (Pubmed Central) -  Dec 8, 2023   
    All patients with PAI were on a stable GC replacement regimen with a median dose of 25 mg hydrocortisone per day...In patients with different etiologies of PAI, distinct differences in T and NK cell-phenotypes became apparent despite the use of same GC preparation and dose. Our results highlight unsuspected differences in immune cell composition and function in PAI patients of different causes and suggest disease-specific alterations that might necessitate disease-specific treatment.
  • ||||||||||  triamcinolone acetonide / Generic mfg., 5-fluorouracil / Generic mfg.
    Journal:  Transdermal Transfersome Nanogels Control Hypertrophic Scar Formation via Synergy of Macrophage Phenotype-Switching and Anti-Fibrosis Effect. (Pubmed Central) -  Dec 8, 2023   
    According to the in vitro/vivo results, TA/Fu-TSs not only promote macrophage phenotype-switching to inhibit inflammation by interleukin-related pathways, but also suppress fibrosis to remodel extracellular matrix by collagen-related pathways. Therefore, TA/Fu-TSs overcome prolonged inflammation and excessive fibrosis in emerging HS tissues, and provide an effective therapeutic strategy for controlling HS formation via their synergy of macrophage phenotype-switching and anti-fibrosis effect.
  • ||||||||||  Empliciti (elotuzumab) / AbbVie, BMS
    New trial:  A Study to Evaluate the Safety of Empliciti (clinicaltrials.gov) -  Dec 8, 2023   
    P=N/A,  N=27, Not yet recruiting, 
  • ||||||||||  Zolinza (vorinostat) / Merck (MSD)
    Trial completion date, Trial primary completion date:  QUAD: A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) -  Dec 8, 2023   
    P1/2,  N=17, Active, not recruiting, 
    Therefore, TA/Fu-TSs overcome prolonged inflammation and excessive fibrosis in emerging HS tissues, and provide an effective therapeutic strategy for controlling HS formation via their synergy of macrophage phenotype-switching and anti-fibrosis effect. Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Nov 2023 --> Nov 2024